The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia
Key facts
- Who runs it
- Mian Muhammad Hassan Ahmed
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 60 people, planned
- Started
- May 2025
- Planned end
- Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Melatonin
- Record updated
- 29 April 2025
Who can take part
- Age
- 1 month to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- 1 month to 12 years
- Both genders
- Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition
Who cannot take part
- Hospitalized within 14 days prior to the study
- Currently taking melatonin
- Active varicella or herpes simplex infection
- Allergy to the study medication
- Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care
- Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
- Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption
- Known TB exposure
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Pneumonia childhood
This trial is currently available in Pakistan.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone.
Read full original descriptionShow less
The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone.
The control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.
The 2 groups in the trial
- Standard TreatmentNo study treatment, for comparison
Standard treatment - Antibiotic such as ampicillin in a dose of 50mg//kg/dose x TDS
- Adjuvant TherapyTreatment being tested
Standard Treatment along with Melatonin @ 1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days
Treatment: Melatonin
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06949904, who can take part
- Record updated
- 29 April 2025